| goserelin acetate / Generic mfg. |
ACTRN12613000107729: The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from China |
|
|
| Active, not recruiting | 4 | 100 | | | Changhai Hospital, Second Military Medical University, Changhai hospital' s" 1255"construction plan | prostate cancer | | | | |
ChiCTR-TRC-08000068: Randomized controlled study about the influence of postoperative use of GnRHa on recurrence and pregnancy rate in moderate or severe endometriosis |
|
|
| Recruiting | 4 | 60 | | No intervention. Begin spontaneous pregnancy immediately after inclusion ;GnRHa (Zoladex) for 6 courses of treatment, then begin spontaneous pregnancy | Women's Hospital, School of Medicine, Zhejiang University; Level of the institution：, Self-funded | Endometriosis | | | | |
2006-001909-28: Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de la recidiva bioquímica del cáncer de próstata tratado con radioterapia. |
|
|
| Ongoing | 4 | 180 | Europe | BUSERELINA, GOSERELINA, LEUPRORELINA, TRIPTORELINA, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL | Grupo GICOR | Cáncer de próstata tratado con radioterapia y que presenta recidiva bioquímica. | | | | |
2007-003137-17: Tratamiento neoadyuvante con quimioterapia (Taxotere) y hormonoterapia en cáncer de próstata localizado de alto riesgo. |
|
|
| Ongoing | 4 | 45 | Europe | Docetaxel, Triptorelina, Goserelina, Leuprorelina, Taxotere, Casodex, Taxotere, Casodex | Grupo de Investigación en Oncología Médica del Hospital de Navarra | Pacientes con cáncer de próstata localizado de alto riesgo. | | | | |
| Not yet recruiting | 4 | 100 | | VISANNE 2MG Tablet once daily ;subcutaneous Goserelin acetate injections (3.6 mg/4 weeks, GoserelinAcetateSustained-ReleaseDepot) | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, no | adenomyosis | | | | |
| Recruiting | 4 | 40 | RoW | Zoladex, Gnrh, Visanne, Dienogest | Mansoura University | Endometriosis | 11/21 | 12/21 | | |
| Ongoing | 4 | 137 | Europe | ribociclib, Zoladex, Tamoxifeno, LEE011, Film-coated tablet, Implant, Tablet, Kisqali, Goserelin, Tamoxifeno Farmoz | Novartis Pharma AG, Novartis Pharma AG | HR+, HER2- advanced or metastatic breast cancer, advanced or metastatic breast cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04248621: Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients |
|
|
| Recruiting | 4 | 164 | RoW | Leuprorelin, Leuprorelin acetate, Goserelin, Goserelin acetate, Triptorelin, Triptorelin acetate, Degarelix, Degarelix acetate, Bicalutamide, Casodex, Flutamide, Niftolide, Maximum androgen blockade, LHRN agonist and antiandrogen | Wonju Severance Christian Hospital, Eulji University Hospital | Prostatic Neoplasms | 04/22 | 12/22 | | |
ChiCTR2000034693: Multi-center, Prospective Study to Investigate the Efficacy and Safety of Zoladex (Goserelin Acetate) 10.8 mg Prior to Surgery in Premenopausal Women with Symptomatic Uterine Fibroids |
|
|
| Not yet recruiting | 4 | 150 | | one depot of Zoladex 10.8mg | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, AstraZeneca Investment (China) Ltd.,Co. | Uterine fibroids | | | | |
ChiCTR2200059548: Comparison of clinical efficacy and incidence of uterine bleeding with different doses of GnRH-a in the treatment of adenomyosis in different periods of the menstrual cycle |
|
|
| Recruiting | 4 | 180 | | A 10.8 mg goserelin acetate sustained-release implant is subcutaneously injected every 12 weeks, and a total of 1-2 injections are given according to the patient's condition ;A 3.6 mg goserelin acetate sustained-release implant is subcutaneously injected every 4 weeks, and a total of 3-6 injections are given according to the patient's condition | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, None | Adenomyosis | | | | |
| Terminated | 4 | 21 | US | Ribociclib, KISQALI | Georgetown University, Medstar Health Research Institute, Breast Cancer Research Foundation, Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) | Breast Cancer | 10/23 | 10/23 | | |
ChiCTR2300076106: Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer |
|
|
| Recruiting | 4 | | China | Airui'en (rezvilutamide) - Jiangsu Hengrui Pharma, goserelin acetate - Generic mfg. | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology | Prostate cancer | | | | |
| Not yet recruiting | 4 | 120 | US | Goserelin 3.6 MG, Zoladex, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g), Estradiol / Levonorgestrel Transdermal System [Climara Pro], Placebo Patch | Bradley Nindl, U.S. Army Medical Research and Development Command | Musculoskeletal Injury, Hypogonadism | 08/26 | 08/26 | | |
| Recruiting | 4 | 418 | RoW | Ovarian function suppression with endocrine treatments | Gangnam Severance Hospital, Seoul National University | Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer, Premenopausal Breast Cancer, Node-positive Breast Cancer | 01/28 | 01/33 | | |
| Recruiting | 4 | 137 | Europe, Japan, US, RoW | Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant | Novartis Pharmaceuticals, Novartis Pharma AG | Metastatic Breast Cancer | 02/30 | 03/30 | | |
| Recruiting | 4 | 228 | US | Gonadotropin Releasing Hormone Agonists (GNRH), Leuprolide, Goserelin, Androgen receptor (AR) inhibitor, Bicalutamide, Flutamide, Enzalutamide, Placebo | University of Colorado, Denver | Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease | 03/28 | 03/28 | | |
